The Future of Acquired TTP

August 31st 2021, 1:00pm


X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment.

Treatment Considerations for Caplacizumab

August 26th 2021, 1:00pm


X. Long Zheng, MD, PhD, explains when physicians should administer caplacizumab after suspecting a diagnosis of acquired TTP, and discusses the risk of relapse or refractory disease.

Using Caplacizumab to Treat Acquired TTP

August 24th 2021, 1:00pm


An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial.

Treatment Options for Acquired TTP

August 19th 2021, 1:00pm


X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider.

Diagnostic Approach to Acquired TTP

August 17th 2021, 1:00pm


A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing.

Overview of Acquired Thrombotic Thrombocytopenic Purpura

August 13th 2021, 6:51pm


X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation.

ACIP Votes to Lift Pause on J&J COVID-19 Vaccine

April 23rd 2021, 9:32pm


The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.

Carfilzomib, Bortezomib Combo Shows Potential for Reducing Tumor Growth in Melanoma Cells

April 15th 2021, 3:45pm


The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.

CDC, FDA Call for Pause of J&J COVID-19 Vaccine After Safety Concerns Around Clotting

April 13th 2021, 3:18pm


After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.

Bortezomib Appears to Increase Fall Risk in Elderly Patients With MM, Study Suggests

April 9th 2021, 11:45am


Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.